Core Viewpoint - The recent birth of genetically modified wolf pups, resembling the extinct dire wolf, marks a significant achievement in de-extinction technology, raising questions about the implications of reviving extinct species and the intersection of science and ethics [7][9][13]. Group 1: Scientific Achievement - Colossal Biosciences announced the successful revival of the dire wolf, claiming it as the first case of resurrecting an extinct animal through ancient DNA extraction and gene editing [9][11]. - The dire wolf's genome was compared with that of modern gray wolves, revealing a 99.3% similarity, with 80 key gene differences identified [11][13]. - Using CRISPR technology, 14 genes in gray wolf embryos were modified to incorporate traits typical of the dire wolf, leading to the birth of three pups in 2024 and 2025 [11][13]. Group 2: Controversy and Definition - There is debate within the scientific community regarding the definition of "revival," with some experts arguing that the modified wolves are more like hybrid wolves than true dire wolves, as 99.9% of their genome remains gray wolf [13][15]. - Critics emphasize that true revival of extinct species may be impossible due to the degradation of ancient DNA, which complicates the cloning process [15][20]. Group 3: Ethical and Ecological Considerations - The project raises ethical questions about humanity's right to alter natural evolutionary processes and the potential ecological impacts of introducing modified species into existing ecosystems [20][21]. - Concerns exist regarding the unforeseen consequences of releasing genetically modified organisms into the wild, with experts warning of potential ecological disruptions [20][21]. - Colossal Biosciences aims to create "functional replicas" of extinct species to restore ecological functions and enhance biodiversity, rather than achieving a perfect genetic replica [15][20]. Group 4: Future Aspirations and Challenges - Colossal Biosciences has plans to revive other extinct species, such as the woolly mammoth and the dodo, with the goal of promoting vegetation recovery in the Arctic tundra to combat climate change [16][18]. - The company has already made strides in mammoth DNA replication, although experts caution that these efforts may be overstated and not fully representative of the original species [18][20]. - The challenges of reviving extinct species include the need for intact DNA, successful embryo development, and appropriate environmental conditions for rearing the animals [21][26].

于全球率先实现了大片段DNA精准插入技术。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据IPO早知道消息，近日，苏州齐禾生科生物科技有限公司（下称"齐禾生科"）完成超2亿元人民币 A轮融资。本次融资由知名基金和老股东共同投资，凯乘资本将继续助力后续A+轮融资。所筹资金将 主要用于公司基因编辑技术的深度研发、基因编辑产品管线的优化与拓展、及商业化平台落地，进一 步提升公司在生物技术产业领域的核心竞争力与市场影响力。 齐禾生科创立于2021年，专注于开发自主可控新型基因编辑技术、创制卓越生物性状和产品。成立 后，公司在基因编辑新工具挖掘、自主知识产权基因编辑工具优化、安全高效递送系统开发和突破性 种质资源创制等多方面均取得显著进展，构建了以SEEDIT™平台为核心的全链条技术平台，商业化 进程位居行业前沿，获2张安全证书，且成为首个获美国USDA豁免的中国企业。 齐禾生科以国家战略需求为导向，目前已经建立起了全球领先的独立自主可控的基因编辑技术体系。 在核酸酶、碱基编辑和引导编辑的基础上，公司在全球率先实现了大片段DNA精准插入技术，为基 于基因堆叠的生物育种和植物合成生物制造产业 ...